Reading-FREE Markers for Early Detection of Developmental Dyslexia
Launched by UNIVERSITÀ VITA-SALUTE SAN RAFFAELE · Jul 8, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This longitudinal study, titled "Longitudinal assessment of multidomain reading-FREE neurocognitive markers for early detection of Developmental Dyslexia (FREE-DD)", investigates early neurocognitive predictors of developmental dyslexia (DD) and related reading disorders in children born preterm (PTB), as compared to children born at term (ATB). Children born preterm are at elevated risk for neurodevelopmental vulnerabilities, including difficulties with language, attention, and reading acquisition, yet early identification of these risks remains limited.
The main objective of the study is...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For Preterm-Born (PTB) Children:
- • Born preterm (i.e., gestational age \< 39 weeks)
- • Aged between 6 and 9 years at enrollment
- • Absence of structural brain lesions (as assessed by prior clinical imaging)
- • Italian as the first language (L1)
- • Right-hand dominant
- • Male or female
- For At-Term-Born (ATB) Children:
- • Born at term (i.e., gestational age between 39 and 42 weeks)
- • Aged between 6 and 9 years at enrollment
- • Absence of structural brain lesions (as assessed by prior clinical imaging)
- • Italian as the first language (L1)
- • Right-hand dominant
- • Male or female
- Exclusion Criteria:
- For Preterm-Born (PTB) Children:
- • History of congenital infections
- • Diagnosis of Multiple Congenital Anomalies Syndrome
- • Presence of focal intracerebral parenchymal lesions
- • Pathological findings on conventional MRI
- For At-Term-Born (ATB) Children:
- • Presence of first-degree relatives diagnosed with developmental dyslexia (DD)
- • Diagnosis of other learning or behavioral disorders
- • Contraindications to MRI (e.g., metal implants, severe claustrophobia)
About Università Vita Salute San Raffaele
Università Vita-Salute San Raffaele is a prestigious Italian academic institution renowned for its commitment to advancing healthcare through innovative research and education. Located in Milan, it integrates cutting-edge scientific inquiry with clinical practice, fostering interdisciplinary collaboration among healthcare professionals. The university is dedicated to improving patient outcomes and public health by conducting rigorous clinical trials that adhere to the highest ethical standards. Its focus spans various medical fields, leveraging state-of-the-art facilities and a strong network of partnerships to drive advancements in medical science and contribute to the global healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, Mi, Italy
Patients applied
Trial Officials
Andrea Falini, Doctor of Medicine
Principal Investigator
1. Vita-Salute San Raffaele University, Milan, Italy 2. Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele, Milan, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported